Skip to main content


Fig. 4 | Cardiovascular Diabetology

Fig. 4

From: Class effects of SGLT2 inhibitors on cardiorenal outcomes

Fig. 4

Heart failure hospitalization (HHF), HHF and cardiovascular (CV) death, and major adverse cardiovascular event (MACE) relative risk reductions (RRRs) in the Dapagliflozin Effect on CardiovascuLAR Events (DECLARE-TIMI 58), CANagliflozin CardioVascular Assessment Study (CANVAS) Program, Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients–Removing Excess Glucose (EMPA–REG OUTCOME), and Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trials. Statistical outcomes displayed as RRR, p-value. RRRs were calculated from hazard ratios

Back to article page